



Contact
Troy Kehoe
JavaCulture Agency
630-803-4436
troy@javacultureagency.com

For Immediate Release

Long Grove Pharmaceuticals Launches Triamcinolone Acetonide Injectable Suspension, USP

FDA-Approved Product Expands Generic Options for Long-Acting Glucocorticoid Therapy and Marks First Product Shipment for Emerging Generics Leader

ROSEMONT, Ill. – [Long Grove Pharmaceuticals®](#), founded in 2019 by strategic health care investor Water Street Healthcare Partners, today announced the launch of its first generic to market, Triamcinolone Acetonide Injectable Suspension, USP. The FDA-approved generic is now available and is indicated for intramuscular and intra-articular use for multiple conditions including the treatment of various types of arthritis.

Triamcinolone Acetonide Injectable Suspension, USP is an AB Rated generic for Bristol Myers Squibb's Kenalog®-40, is TAA Compliant and made in the European Union. It is available in both single-dose and multiple-dose vial presentations and its vial stopper does not contain natural rubber latex.

“We are excited about the launch of Triamcinolone Acetonide,” said Dan Robins, Ph.D., President & CEO of Long Grove Pharmaceuticals. “This successful launch required hard work from the entire team here at Long Grove. We are proud of this significant accomplishment and look forward to further expanding our portfolio.”

Long Grove Pharmaceuticals' Triamcinolone Acetonide Injectable Suspension, USP is the first in a series of planned launches in the coming year for the company as an emerging leader in the next generation of generic pharmaceuticals. The pharmaceutical company focuses on complex generics, including injectables and topical products, and is committed to improving customer choice while increasing access for patients.

About Long Grove Pharmaceuticals®

Long Grove Pharmaceuticals was established in 2019 by Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry. The company is part of Capstone Development Services, which has been developing products in partnership with the world's premier pharmaceutical and medical device organizations since 2013. Combining decades of collective leadership experience with a portfolio of specialized, complex generic drug formulations, Long Grove Pharmaceuticals is poised to innovate across the generic injectable and topical markets.

For full prescribing information for Triamcinolone Acetonide Injectable Suspension, USP, please visit <https://longgrovepharma.com/triamcinolone-acetonide-injectable-suspension-usp/>.